Less is More: Biomimetic Hybrid Membrane Nanocarriers for Highly Efficient Tumor Targeted Drug Delivery
Small · 2025
DOI: 10.1002/smll.202407245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Siwen Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guan…. Hauptthemen laut MEDLINE: Nanoparticles, Drug Delivery Systems, Biomimetic Materials, Drug Carriers. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Biomimetic camouflaged nanocarriers coated with cancer cell membranes (CCMs) have attracted considerable research attention for drug delivery application. CCM‐camouflaged nanocarriers have inherent tumor‐homologous targeting ability. However, they enter cancer cells via endocytosis, which is not efficient for drug delivery. Switching the internalization mechanism to membrane fusion may enhance their delivery efficiency. In this study, an innovative biomimetic‐targeting nanocarrier is designed by hybridizing CCMs with pH‐sensitive liposomes (1,2‐dioleoyl‐sn‐glycero‐3‐phosphoethanolamine liposomes, DOPE‐Lipo), named as CCMpHD. The presence of CCMs makes the nanocarriers capable of homologous targeting, and the DOPE‐Lipo hybrid allows the nanocarriers to achieve efficient internalization via membrane fusion. Notably, the cellular uptake of CCMpHD is significantly higher than that of the CCMs. The most efficient delivery is achieved with 1/10 CCMs, which requires remarkably less cell membranes. Doxorubicin (DOX) is used as a model drug to characterize the homologous targeting drug delivery properties of the hybrid nanocarriers. Both in vitro and in vivo experiments demonstrated that the nanocarriers exhibited satisfactory biosafety and enhanced tumor‐targeted delivery. With enhanced delivery efficiency whilst requiring fewer CCMs, these hybrid membrane nanocarriers provides a new strategy for CCM‐based drug delivery in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, P. R. China.
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, P. R. China.
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, 510515, P. R. China.
- Experimental Education/Administration Center, School of Basic Medical Science, Southern Medical University, Guangzhou, 510515, P. R. China.
ORCID-Profile: Bingxia Zhao
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Chen, S., Lan, H., Liu, M., He, C., Li, Q., Zheng, S., Zheng, Y., Wu, Z., Liu, T., & Zhao, B. (2025). Less is More: Biomimetic Hybrid Membrane Nanocarriers for Highly Efficient Tumor Targeted Drug Delivery. Small. https://doi.org/10.1002/smll.202407245
Vancouver
Chen S, Lan H, Liu M, He C, Li Q, Zheng S, et al. Less is More: Biomimetic Hybrid Membrane Nanocarriers for Highly Efficient Tumor Targeted Drug Delivery. Small. 2025. doi:10.1002/smll.202407245
BibTeX
@article{Chen2025,
author = {Chen, Siwen and Lan, Haibo and Liu, Minyi and He, Chenxi and Li, Qiuyu and Zheng, Shuting and Zheng, Yinfei and Wu, Zede and Liu, Tiancai and Zhao, Bingxia},
title = {Less is More: Biomimetic Hybrid Membrane Nanocarriers for Highly Efficient Tumor Targeted Drug Delivery},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202407245}
}
EUVIMED